Builders
For a med spa, gym, chiropractic practice or wellness clinic, the barrier to offering medically supervised services was rarely patient interest. It was the supervising clinician — and everything that came with hiring one.
For a med spa, gym, chiropractic practice or wellness clinic, the barrier to offering medically supervised services was rarely patient interest. It was the supervising clinician — and everything that came with hiring one.
That barrier has a different shape now. What has not changed is the obligation that comes with crossing it.
Practice owners describe a consistent shift. Clients who used to ask what a service felt like now ask what the evidence is. They arrive having read something, often from a source with no clinical oversight at all, and they want a considered answer.
That question is currently going somewhere. If it is not answered in your practice, it is answered by social media or by an unregulated online seller. That is the honest case for offering these services: not that it is a market opportunity, but that the demand exists and is currently being met badly.
We have written separately on why education-led wellness retains clients. This piece is about the operational side.
Historically, adding medically supervised services meant employing or contracting a medical director. For a single-site practice that is a significant fixed cost, a recruitment problem, and an ongoing compliance burden — enough to stop most practices before they start.
The alternative model is a supervising-provider relationship, where licensed providers evaluate patients individually by telehealth and hold clinical responsibility for their own decisions. Bearing works with LocumTele as a partner for exactly this capability.
What that model does and does not change:
It does remove the need to recruit a medical director in order to offer provider-supervised services.
It does not transfer clinical judgement to the practice. The provider evaluates each patient and decides. A practice cannot direct a prescribing decision, and should be sceptical of any arrangement that implies otherwise.
It does not remove your own regulatory obligations. Scope of practice, facility requirements, corporate practice of medicine rules and fee-splitting restrictions vary by state and are your responsibility to verify. This is a conversation with your own attorney and your malpractice carrier before it is a conversation about services.
This has to be stated plainly, because it is where most marketing in this space becomes misleading.
Many peptides used in optimisation medicine are compounded preparations. They are not FDA-approved drugs for these indications. Compounded products are prepared by 503A or 503B pharmacies under a different regulatory framework from approved drugs — they do not undergo the same pre-market review for safety and efficacy for the use in question.
Some peptides are FDA-approved for specific indications. Using them outside those indications is off-label prescribing, which is lawful and common in medicine, and which is not the same thing as an approved use.
Both of these facts belong in your patient conversations, not in the small print. A practice that blurs the line between "compounded" and "FDA-approved" is creating a liability it does not need and a consent process that will not hold up.
The evidence base also varies enormously by compound. Some have substantial human data. Others have almost none, and a practice offering them should be able to say which is which without reaching for a brochure.
Cash-pay service lines have real operational advantages that do not depend on any growth claim: no prior authorisation, no claims submission, no reimbursement lag, and pricing you set. For a practice already carrying administrative burden, that is a materially simpler operating model.
We are not going to tell you it is the fastest-growing revenue line in the sector. That claim circulates widely and we could not substantiate it against an authoritative source, so it does not appear here. If someone selling you a programme leads with it, ask them for the data.
What can be said without overstating: patient interest in longevity and optimisation medicine has moved from niche towards mainstream, these services are typically paid directly, and protocols involving follow-up and monitoring produce more continuity of care than one-off treatments do. Whether that works economically in your practice depends on your patient base, your pricing and your capacity — and it is worth modelling before committing.
The practices that do well with this are the ones that could defend every claim they make to a regulator, a carrier and a patient's own physician.
The operational barrier to offering medically supervised wellness is lower than it was. The clinical and regulatory obligations are exactly what they always were, and a model that makes the first part easier does not soften the second.
Practices that treat this as a service line to build carefully tend to do well. Practices that treat it as a revenue line to bolt on tend to find out why the barrier existed.
If you are weighing it up and want to talk it through, get in touch.
Ready when you are
Read the library first. When you want to act, start with a conversation with a licensed provider, entirely by telehealth.